MedPath

Comparison of subacromial Ketorolac, betamethazone LA and triamcinolon injection in treatment of impingement syndrome

Phase 2
Conditions
Impingement syndrome of shoulder.
Impingement syndrome of shoulder
Registration Number
IRCT2017042927797N2
Lead Sponsor
Vice Chancellor of Reaserch and Technology, Babol University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
105
Inclusion Criteria

all people with shoulder pain referred to orthopedic clinics and diagnostic imaging in the diagnosis of shoulder impingement syndrome has been laid for them and their consent to participate in the study. Exclusion criteria: patients with all of the diagnosis except impingement syndrome; Do not go to the next follow up; do not have a history of shoulder dislocation or fracture or a systemic disease that affects the joint and soft tissue .

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Determine the function of the patient. Timepoint: Before injection, weeks 2, 4 and 6 after injection. Method of measurement: By Oxford Shoulder Score questionnaire.;Patient pain severity. Timepoint: Before injection, weeks 2, 4 and 6 after injection. Method of measurement: By Visual Analogus Scale questionnaire.
Secondary Outcome Measures
NameTimeMethod
Tendon Rupture. Timepoint: weeks 2, 4 and 6 after injection. Method of measurement: Physical Examination.;Injection site infection. Timepoint: weeks 2, 4 and 6 after injection. Method of measurement: Observation.
© Copyright 2025. All Rights Reserved by MedPath